Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Regeneron
Company Monitoring Page for Regeneron
job ratings for Regeneron
12/30/22
industry:
Big Pharma
company:
Regeneron
job rating:
1
My boss is abusive
10/21/17
industry:
Bio-Tech
job title:
Medical Specialist Immunology
company:
Regeneron
job rating:
7
Best company I’ve ever worked for. Best DM, best upper management, focus strongly on older, successful reps.
06/06/17
industry:
Bio pharmaceutical Industry
company:
Regeneron
job rating:
5
I have lived my job until lately. We are being forced to become Moreno like Sanofi. I now want to leave my job and go elsewhere because of it.
05/29/17
industry:
pharma
company:
Regeneron
job rating:
1
culture
01/29/17
industry:
Biotechnology
company:
Regeneron
job rating:
7
Transparency is great! pay is decent. Bonus opportunity is good.
latest headlines for company on cafepharma
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
Tags:
FDA
,
Sandoz
,
Novartis
,
Gilead Sciences
,
Pfizer
,
Neurocrine
,
Regeneron
,
Ipsen
,
Revance Therapeutics
,
Delcath Systems
,
Janssen
,
Galera Therapeutics
,
Biogen
,
Roche
,
Mesoblast
,
Taiho Oncology
Regeneron, J&J Win HHS Funding to Develop Next-Gen COVID Products
BioSpace
Wed, 08/23/23 - 09:54 am
Tags:
HHS
,
Regeneron
,
JNJ
,
COVID-19
,
funding
Regeneron Expands Eylea’s Label with High-Dose Approval
BioSpace
Mon, 08/21/23 - 10:44 am
Tags:
Regeneron
,
Eylea
,
FDA
Regeneron’s Antibody Gets FDA Approval for Ultra-Rare Hereditary Disease
BioSpace
Sun, 08/20/23 - 05:17 pm
Tags:
Regeneron
,
FDA
,
CHAPLE disease
,
Veopoz
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
Mon, 08/14/23 - 11:29 am
Tags:
FDA
,
Ipsen
,
Revance Therapeutics
,
Neurocrine
,
Regeneron
,
palovarotene
,
fibrodysplasia ossificans progressiva
,
Daxxify
,
cervical dystonia
,
Ingrezza
,
chorea
,
Huntington's disease
,
pozelimab
,
CHAPLE disease
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Fierce Pharma
Thu, 08/10/23 - 09:49 pm
Tags:
Regeneron
,
Eylea
,
age-related macular degeneration
,
FDA
Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration
Fierce Biotech
Wed, 08/9/23 - 10:10 am
Tags:
Regeneron
,
hearing loss
,
Decibel Therapeutics
,
gene therapy
,
M&A
Regeneron expects FDA decision on higher-dose Eylea this year
Reuters
Thu, 08/3/23 - 06:40 pm
Tags:
Regeneron
,
Eylea
,
FDA
Moderna, Regeneron post solid earnings, eye a strong finish to 2023
Medical Marketing and Media
Thu, 08/3/23 - 11:23 am
Tags:
earnings
,
Moderna Therapeutics
,
Regeneron
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Fierce Biotech
Thu, 08/3/23 - 10:17 am
Tags:
Regeneron
,
prostate cancer
,
clinical trials
,
patient deaths
,
REGN5678
,
bispecific antibodies
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Fri, 07/28/23 - 11:46 am
Tags:
Ipsen
,
palovarotene
,
fibrodysplasia ossificans progressiva
,
Regeneron
,
CHAPLE disease
,
pozelimab
,
Biomarin
,
Voxzogo
,
achondroplasia
,
Santhera Pharmaceuticals
,
vamorolone
,
DMD
,
Springworks
,
nirogacestat
,
desmoid tumors
Scratching the surface of the urticaria pipeline
EP Vantage
Thu, 07/20/23 - 10:00 am
Tags:
chronic urticaria
,
Sanofi
,
Dupixent
,
Regeneron
,
Novartis
,
Roche
,
Xolair
,
Allakos
,
AstraZeneca
,
Celldex Therapeutics
Dupixent goes back-to-back as top Rx, OTC pharma brand in June
Medical Marketing and Media
Thu, 07/6/23 - 10:16 am
Tags:
Dupixent
,
Sanofi
,
Regeneron
Is Regeneron's Stock in Trouble After This FDA Rejection?
Motley Fool
Thu, 07/6/23 - 10:15 am
Tags:
Regeneron
,
Eylea
,
FDA
Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups
Fierce Pharma
Tue, 06/27/23 - 10:24 pm
Tags:
Regeneron
,
Eylea
,
FDA
Aslan sells Japanese rights to would-be Dupixent rival for $12M
Fierce Biotech
Thu, 06/22/23 - 10:41 pm
Tags:
Aslan
,
Dupixent
,
Japan
,
eczema
,
Sanofi
,
Regeneron
,
eblasakimab
Dupixent reclaims throne as top Rx, OTC pharma brand in May
Medical Marketing and Media
Tue, 06/6/23 - 11:13 am
Tags:
Dupixent
,
Sanofi
,
Regeneron
,
DTC advertising
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
Tags:
FDA
,
Albireo Pharma
,
Aldeyra Therapeutics
,
Alvotech
,
Amneal Pharmaceuticals
,
Argenx
,
ARS Pharmaceuticals
,
AstraZeneca
,
Bayer
,
Bio-Thera Solutions
,
Biogen
,
BioMarin Pharmaceutical
,
Bristol Myers Squibb
,
Eisai
,
Eton Pharmaceuticals
,
F2G
,
Fabre-Kramer Pharmaceuticals
,
Fresenius
,
GSK
,
Intercept Pharmaceuticals
,
Ipsen
,
Ironwood Pharmaceuticals
,
Merck
,
Novaliq
,
Pfizer
,
Regeneron
,
Roche
,
Sanofi
,
Sarepta Therapeutics
,
Shionogi
,
Swedish Orphan Biovitrum
,
Takeda
,
Teva Pharmaceutica
,
UCB Pharma
ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma
Fierce Biotech
Thu, 05/25/23 - 08:49 pm
Tags:
ASCO 2023
,
Regeneron
,
advanced melanoma
,
fianlimab
Sanofi, Regeneron flesh out COPD data with Dupixent
Pharmaphorum
Mon, 05/22/23 - 10:16 am
Tags:
Sanofi
,
Regeneron
,
COPD
,
Dupixent
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
cafepharma is a: rock, tree, site
*
Fill in the blank.